Clinical research study for people with early-stage Alzheimer’s Disease | Alzheimer's Prevention Registry

You are here

Clinical research study for people with early-stage Alzheimer’s Disease

(Study Status: Recruiting)

Study Type: 
Studies for People w/ Memory Impairment
Eligible Age Range: 
55+
About The Study: 

Local doctors are currently conducting a clinical research study of an investigational drug for people with early-stage Alzheimer’s disease. In this research study, they want to evaluate the investigational drug for its safety and effectiveness on memory and thinking skills, and compare it with placebo, which looks like the investigational drug, but contains no active ingredients and does not have any effect on your condition. If you have been diagnosed with early-stage Alzheimer’s and have not taken any prescription drugs for your condition within 3 months prior to the study, you may be eligible for this study.

Purpose: 

Currently, there are approved treatments to slow the progression of Alzheimer’s, but these treatments are for people who are no longer in the early stage of the disease. Without a treatment option to slow progression, people with early-stage Alzheimer’s are at risk of developing a more advanced form of Alzheimer’s dementia. 

As a result, researchers are exploring possible treatment options for the symptoms of early-stage Alzheimer’s disease. In this study, the investigational drug, is being evaluated to learn more about the safety and effectiveness on memory and thinking skills in people with early-stage Alzheimer’s. 

The results of this research study will provide more information about the investigational drug and whether it could one day be used as an early-stage Alzheimer’s treatment.
 

What is Involved: 

You will be randomly assigned (like drawing a number out of a hat) to receive either the investigational drug or placebo, which looks like the investigational drug, but contains no active ingredients. To prevent opinions about the investigational drug or placebo from affecting the study results, you, your study doctor, and the study staff will not know which study drug you are receiving. 

You will take your assigned study drug twice a day for approximately 12 weeks. Total participation in the study will last about 23 weeks and includes around 10 visits to the study center, with the possibility that 2 of the visits are conducted over the phone.
During your study center visits, doctors and the study staff will use various tests and assessments to evaluate your health and progress. These include, but are not limited to:

  • Review of your medical history 
  • Blood and urine sample collections 
  • Vital signs measurements (blood pressure and pulse rate) 
  • Questions about your thinking capabilities, mood assessments, and mental status and behavior 
  • Physical and nervous system exams 
  • Liver function tests
  • PET Scan (scan of the body) or spinal fluid sample 
  • Reviews of medications you are taking or have taken 
  • Reviews of any side effects you experience
Eligibility Requirements: 

To pre-qualify for this study, you must: 

  • Be 55 years of age or older 
  • Be diagnosed with early-stage Alzheimer’s disease 
  • Have a reliable study partner (family member, friend, guardian, etc.) who will be in close contact with you throughout the study and accompany you to clinic visits  
  • Must meet other study criteria   

All study-related visits, tests, and the study drug will be provided at no cost. In addition, reimbursement for study-related time and travel may be provided.

Select a Study Site Below:

Study Locations/Sites